{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:31:30Z","timestamp":1786728690951,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction, and in over 80% of cases, antibodies are identified against the nicotinic type of acetylcholine receptor (AChR) on the muscle endplate. Despite the availability of various treatment options, patients with MG experience relapses and remission during the course of the disease. Aims and Objective: To understand the clinical profile, predictors of outcomes in acetyl choline receptor (AChR) antibody positive generalized MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a retrospective, single-centre, observational study of 108 patients with AChR positive generalized MG. We collected data on clinical and demographical profiles, treatments received, and treatment responses from those who fulfilled inclusion criteria over a mean follow up period of 33.75 \u00b17.30 months. Clinical outcomes were studied in terms of the type of remission and crisis or disease exacerbations patients had, considering different variables and treatment received.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We found the commonest initial symptoms were ocular or oculo-bulbar, which progressed to generalized MG in the first year of disease onset. 36 (33.3%) patients experienced a crisis requiring mechanical ventilation within a mean period of 9.4 \u00b14.77 months from the disease onset. Multivariate regression analysis showed late-onset MG (age of onset between 50-70 years) and treatment with rituximab were better correlated with remission, (odd ratio of 4.7; 95 % CI ,1.12 -12.6;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.05 and odd ratio of 4.56; 95 % CI ,1.2 -10.04;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.05) respectively. While treatment with Mycofenolate Mofetile (MMF) was associated with a higher number of relapses (odd ratio of 1.8; 95 % CI ,0.08 -0.96;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.05). Treatment with Rituximab showed a higher rate of remission as compared to treatment refractory (TR) on conventional immunosuppressant therapy (IST). Out of 35(32 %) thymoma patients, 21 patients underwent thymectomy and these patients showed significantly greater rate of remission as compared both thymoma patients who denied thymectomy as a treatment option (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 10 ;55.60 % vs\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      = 4; 23.50%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this study of AChR antibody positive generalized MG patients, we found that nearly one-third of them experienced myasthenic crisis despite receiving the best medical care. Rituximab appeared to be effective in the treatment of refractory MG and those who failed thymectomy. Thymectomy was associated with better outcomes in patients, both with or without a thymoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_186_23","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:01:50Z","timestamp":1692979310000},"page":"395-400","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Clinical Outcome in AChR-Positive Generalized Myasthenia Gravis: A Retrospective Observational Study"],"prefix":"10.4103","volume":"26","author":[{"given":"Pawan T.","family":"Ojha","sequence":"first","affiliation":[{"name":"Department of Neurology, Grant Government Medical College and Sir J. J. Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet M.","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"Department of Neurology, Grant Government Medical College and Sir J. J. Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Grant Government Medical College and Sir J. J. Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Jagiasi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Grant Government Medical College and Sir J. J. Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Neurology, Grant Government Medical College and Sir J. J. Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis, prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"R3-20240828","first-page":"874680","article-title":"Myasthenia gravis:A review","volume":"2012","author":"Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.293.15.1906","article-title":"Does this patient have myasthenia gravis?","volume":"293","author":"Scherer","year":"2005","journal-title":"JAMA"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis \u2013experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia:A retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab:A retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis:Recommendation for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"R16-20240828","first-page":"933","article-title":"Clinical profile of myasthenia gravis","volume":"46","author":"Saha","year":"1998","journal-title":"J Assoc Physicians India"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4103\/0028-3886.144438","article-title":"Once myasthenic, always myasthenic?Observations on the behavior and prognosis of myasthenia gravis in a cohort of 100 patients","volume":"62","author":"Khadilkar","year":"2014","journal-title":"Neurol India"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis:A long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2169\/internalmedicine.47.0735","article-title":"Dysgeusia limited to sweet taste in myasthenia gravis","volume":"47","author":"Nakazato","year":"2008","journal-title":"Intern Med"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","article-title":"Outcome measures and treatment effectiveness in late onset myasthenia gravis","volume":"2","author":"Pasqualin","year":"2020","journal-title":"Neurol Res Pract"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pbj.2017.02.002","article-title":"Rituximab in generalized myasthenia gravis:Clinical, quality of life and cost\u2013utility analysis","volume":"2","author":"Peres","year":"2017","journal-title":"Porto Biomed J"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-lasting Rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front Immunol"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2147\/NDT.S3309","article-title":"Mycophenolate mofetil for myasthenia gravis:A clear and present controversy","volume":"4","author":"Heatwole","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated myasthenia gravis","volume":"28","author":"\u00c1lvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1016\/j.ijso.2021.100381","article-title":"Thymectomy for non-thymomatous myasthenia gravis:Short and long term outcomes, a single-center 10 years'experience","volume":"35","author":"Baram","year":"2021","journal-title":"Int J Surg Open"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-018-0837-z","article-title":"Thymectomy in nonthymomatous myasthenia gravis-systematic review and meta-analysis","volume":"13","author":"Cataneo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12883-022-02564-x","article-title":"Impact of COVID-19 infection among myasthenia gravis patients-A cerner real-world data\u2122 study","volume":"22","author":"Digala","year":"2022","journal-title":"BMC Neurol"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"107140","DOI":"10.1016\/j.clineuro.2022.107140","article-title":"Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients:A systematic review","volume":"213","author":"Abbas","year":"2022","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_186_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:30:34Z","timestamp":1786725034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_186_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_186_23","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}